Active, not recruitingPhase 2NCT03546582
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
Studying Squamous cell carcinoma of head and neck
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- RTOG Foundation, Inc.
- Principal Investigator
- Stuart J. Wong, MDRTOG Foundation
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 86 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2029
Study locations (18)
- University of Arizona Cancer Center - North Campus, Tucson, Arizona, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Cleveland Clinic - Weston, Weston, Florida, United States
- University of Louisville, James Graham Brown Cancer Center, Louisville, Kentucky, United States
- Boston Medical Center, Boston, Massachusetts, United States
- Washington University St. Louis, St Louis, Missouri, United States
- Northwell Health, Lake Success, New York, United States
- University of Cincinnati Cancer Center - UC Medical Center, Cincinnati, Ohio, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University, Columbus, Ohio, United States
- Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center Shadyside, Pittsburgh, Pennsylvania, United States
- University of Texas Southwestern, Dallas, Texas, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03546582 on ClinicalTrials.govOther trials for Squamous cell carcinoma of head and neck
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07333274Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE3NCT07026474Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCCUniversität des Saarlandes
- RECRUITINGPHASE1NCT07182149A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid TumorsNormunity AccelCo, Inc.
- RECRUITINGNANCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled TrialTobias Todsen
- RECRUITINGNANCT07180901Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck CancerCentre hospitalier de l'Université de Montréal (CHUM)
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415Local Injection Methylene Blue Combined With Radiation in HNSCC PatientsChina Medical University Hospital
- RECRUITINGPHASE2NCT07088211Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCCShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- RECRUITINGPHASE2NCT07040956A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.West China Hospital
See all trials for Squamous cell carcinoma of head and neck →